With a degree in biological sciences from The University of Cambridge, I joined AstraZeneca in February 2016 from global professional services firm, EY. I have previously worked for OC&C Strategy Consultants and rail construction company Crossrail.
As Associate Director of Strategic Planning and Operations within ECD, I deliver business operations and improvements for Early Clinical Development including managing the ECD scorecard, reporting, communications, online collaboration tools and leading strategic projects. I am passionate about improving our business and making sure we can operate as effectively as possible to deliver the best outcomes for patients.
In October 2016, I founded and became chair of AstraZeneca’s Network of Women in the UK.
AstraZeneca is committed to creating an inclusive workforce and increasing diversity in senior scientific roles. We have trialled blind-screening of CVs to remove unconscious bias to gender, and employ diverse panels for interviews to ensure the best person is recruited.
AstraZeneca’s Women as Leaders programme gives our female scientists a chance to come together to discuss career progression and personal development, with a view to increasing awareness of opportunities and giving them the confidence to pursue these. Those who have attended the programme have seen a 30 per cent promotion rate and gained both sponsors and mentors.
AstraZeneca is committed to creating an inclusive workforce and increasing diversity in senior scientific roles.
IMED Quest 2017 cohort
Identified as one of the ‘Top 100’ talent
Time For Science Award 2016
Annual award for delivering efficiency across ECD
EY’s 21 Women award
One of EY’s talented 21st century women
AstraZeneca Network of Women UK – The successful official launch event on 8 March 2017, International Women’s Day, run jointly with our UK LGBT+ network, AZplus. A proud moment for myself and my fellow network chair
Transitioning from professional services into AstraZeneca and becoming surrounded by inspiring science and part of one of the most promising pipelines in the industry